Replimune’s resubmission for RP1 for melanoma comes amid the departures of FDA leaders in place at the time of the drug’s first two rejections, last summer and again in April.

Original title: “Replimune gives cancer immunotherapy a third try after FDA leadership shakeup”

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

Original title: “Pfizer, Innovent strike $10B cancer drug deal”

Pfizer continues its dealmaking spree by striking a back-heavy partnership with China’s Innovent Biologics to assemble a pipeline of antibody-based therapies for cancer.

Original title: “Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent”

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.

Original title: “CVS obesity drug deal puts Lilly on equal footing with Novo”

Aarskog Scott Syndrome Treatment Market Set to Reach USD 6 83 Billion by 2036 as Advancements in Genetic Diagnostics and Rare Disease Care Expand Global Treatment Access NEWARK Del USA May 28 2026 According to the latest analysis by Future ... Press release - Future Market Insights (FMI) - Aarskog-Scott Syndrome Treatment Market Set to Reach USD 6.83 Billion by 2036 as Advancements in Genetic Diagnostics and Rare Disease Care Expand Global Treatment Access - published on openPR.com Featured Snippet: Key Market Insights • Market Size (2026): USD 3.82 Billion • Forecast Value (2036): USD 6.83 Billion • CAGR (2026-2036): 6.0% • Top Growth Markets: USA and South Korea • Key Drivers: Improving genetic diagnostics, expanding rare disease treatment programs, growing clinical awareness, increasing access to growth hormone therapies • Leading Category Segment: Facial Manifestations • Leading Treatment Segment: Growth Hormone Therapy 👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-16423 Market Overview: Rare Disease Awareness and Genetic Diagnostics Support Long-Term Growth The Aarskog-Scott syndrome treatment market is projected to grow from USD 3.82 billion in 2026 to approximately USD 6.83 billion by 2036, registering a CAGR of 6.0% during the forecast period. This trend is supported by: • Increasing insurance coverage for orphan disease therapies • Growing rare disease clinical network development • Expansion of pediatric endocrinology treatment centres • Rising access to growth hormone therapy programs Healthcare providers are increasingly improving care coordination and treatment accessibility for patients with rare developmental disorders. Growth Hormone Therapy Remains the Largest Treatment Segment Growth hormone therapy continues emerging as the leading treatment category because of: • Strong clinical evidence supporting pediatric growth outcomes • Standardized endocrinology treatment protocols • Increasing insurance reimbursement support • Expansion of rare disease treatment accessibility Pediatric endocrinologists are increasingly relying on hormone-based interventions to improve long-term developmental outcomes.

Original title: “Aarskog-Scott Syndrome Treatment Market Set to Reach USD 6.83 Billion by 2036 as Advancements in Genetic Diagnostics and Rare Disease Care Expand Global Treatment Access”

In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, managing partner at Kurma Partners. We dive into France’s biotech ecosystem and what still needs to happen for more early innovation to translate into investable, scalable biotech.

Original title: “France’s biotech ecosystem: science, capital and scale”

Three experts discuss whether biotech and pharma professionals should try to convince employers to adjust employment offers, mistakes people make during the process and tips for getting it right.

Original title: “Should biopharma professionals negotiate job offers in an employer’s market?”

Looking for a biopharma job in New Jersey? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.

Original title: “11 companies hiring in New Jersey now”

Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to patients who best benefit from them.

Original title: “Verge, following trial failure, rebrands its AI drug discovery ambitions”

Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.

Original title: “Cardio drugmaker Kardigan plans to go public”

The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.

Original title: “Apogee eczema drugs gets Blackstone backing, heads to Phase 3”

Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.

Original title: “Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss”

Under the temporary reign of top food executive Kyle Diamantas, the FDA will sustain programs initiated by former Commissioner Marty Makary, including the Commissioner’s National Priority Voucher initiative.

Original title: “Makary’s reforms will live on at FDA even as leadership turns over”

Eli Lilly continues to spend its GLP-1 landfall with four new deals in the past week, including three in the vaccine space; the obesity leader also touted surgery-like results for its next-gen weight loss drug; Moderna’s stock climbs on the hantavirus “fear trade”; and in oncology, all eyes are on Revolution at ASCO this week.

Original title: “Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds”